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Purpose
In response to advances in the ﬁeld, the College of American Pathologists (CAP), the International
Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP)
recently updated their recommendations for molecular testing for the selection of patients with
lung cancer for treatment with targeted tyrosine kinase inhibitors. ASCO has a policy and set of
procedures for endorsing clinical practice guidelines that have been developed by other professional
organizations.
Methods
The molecular testing guideline was reviewed for developmental rigor by methodologists. Then an
ASCO Expert Panel reviewed the content and the recommendations.
Results
The ASCO Expert Panel determined that the recommendations from the CAP/IASLC/AMP molecular
testing guideline are clear, thorough, and based upon the most relevant scientiﬁc evidence. ASCO
endorsed the guideline with minor modiﬁcations.
Recommendations
This update clariﬁes that any sample with adequate cellularity and preservation may be tested and
that analytical methods must be able to detect mutation in a sample with as little as 20% cancer cells.
It strongly recommends against evaluating epidermal growth factor receptor (EGFR) expression by
immunohistochemistry for selection of patients for EGFR-targeted therapy. New for 2018 are
recommendations for stand-alone ROS1 testing with additional conﬁrmation testing in all patients
with advanced lung adenocarcinoma, and RET, ERBB2 (HER2), KRAS, and MET testing as part of
larger panels. ASCO also recommends stand-alone BRAF testing in patients with advanced lung
adenocarcinoma. Recommendations are also provided for testing methods for lung cancers that
have a nonadenocarcinoma non–small-cell component, for patients with targetable mutations who
have relapsed on targeted therapy, and for testing the presence of circulating cell-free DNA.
Additional information is available at www.asco.org/thoracic-cancer-guidelines and www.asco.org/
guidelineswiki.

ASSOCIATED CONTENT
Appendix
DOI: https://doi.org/10.1200/JCO.
2017.76.7293
Methodology Supplement
DOI: https://doi.org/10.1200/JCO.
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INTRODUCTION

2017.76.7293
DOI: https://doi.org/10.1200/JCO.2017.
76.7293

Expected median survival for patients with advanced
lung cancer is approximately 1 year; however,

treatment with targeted tyrosine kinase inhibitor
(TKI) therapy can improve outcomes for patients
who have certain molecular alterations that can be
identiﬁed by molecular testing.1 In 2013, the College of American Pathologists (CAP)/International
© 2018 by American Society of Clinical Oncology
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THE BOTTOM LINE
Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine
Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/
International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice
Guideline Update
ASCO endorses the Updated Molecular Testing for the Selection of Patients With Lung Cancer for Treatment with Targeted
Tyrosine Kinase Inhibitors Clinical Practice Guideline, with minor modiﬁcations suggested by the ASCO Expert Panel appearing in
bold italics. Additional contextual information added from the CAP/IASLC/AMP guideline narrative is included in italics. A
comparison of the CAP/IASLC/AMP and ASCO recommendations can be found in Tables 1 and 2.
Guideline Question
Which patients with advanced lung cancer should be tested for biomarkers that indicate the likelihood of response to targeted tyrosine
kinase inhibitors (TKIs)? Which samples and genes should be tested, and how should these tests be designed, validated, and executed?
Target Population
Patients with advanced lung cancer (ie, stage IV or other incurable lung cancer).
Target Audience
Medical or surgical oncologists, pathologists, thoracic surgeons, and specialists in pulmonary medicine or interventional radiology.
Methods: An Expert Panel was convened to endorse clinical practice guideline recommendations that were based on a systematic
review of the medical literature.
Key Recommendations
2013 Recommendations that were reaffirmed or updated for 2018:

1. Expert Consensus Opinion: Pathologists may use either cell blocks or smear preparations as suitable specimens for lung
cancer biomarker molecular testing.
2. Expert Consensus Opinion: Laboratories should use, or have available at an external reference laboratory, clinical lung
cancer biomarker molecular testing assays that are able to detect molecular alterations in specimens with as little as 20%
cancer cells.
3. Strong Recommendation: Laboratories should not use epidermal growth factor receptor (EGFR) expression by
immunohistochemistry (IHC) testing to select patients for EGFR-targeted TKI therapy.
4. Recommendation: Physicians should use molecular testing for the appropriate genetic targets on either primary or
metastatic lung lesions to guide initial therapy selection.
5. Recommendation: Pathologists and laboratories should not use EGFR copy number analysis (ie, ﬂuorescent in situ
hybridization or chemiluminescent in situ hybridization) to select patients for EGFR-targeted TKI therapy.
New 2018 Recommendations:
Key Question 1: Which genes should be tested for patients with lung cancer?

1. Recommendation: ROS1 testing should be performed on all patients with advanced lung adenocarcinoma, irrespective of
clinical characteristics.
2. Expert Consensus Opinion: ROS1 IHC may be used as a screening test in patients with advanced lung adenocarcinoma;
however, positive ROS1 IHC results should be conﬁrmed by a molecular or cytogenetic method.
3. Expert Consensus Opinion: BRAF testing should be performed on all patients with advanced lung adenocarcinoma,
irrespective of clinical characteristics.
4. Expert Consensus Opinion: RET molecular testing is not recommended as a routine stand-alone assay outside the context
of a clinical trial. It is appropriate to include RET as part of larger testing panels performed either initially or when routine
EGFR, ALK, BRAF, and ROS1 testing is negative.
(continued on following page)
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THE BOTTOM LINE (CONTINUED)
5. Expert Consensus Opinion: ERBB2 (HER2) molecular testing is not indicated as a routine stand-alone assay outside the
context of a clinical trial. It is appropriate to include ERBB2 (HER2) mutation analysis as part of a larger testing panel
performed either initially or when routine EGFR, ALK, BRAF, and ROS1 testing is negative.
6. Expert Consensus Opinion: KRAS molecular testing is not indicated as a routine stand-alone assay as a sole determinant
of targeted therapy. It is appropriate to include KRAS as part of larger testing panels performed either initially or when
routine EGFR, ALK, BRAF, and ROS1 testing is negative.
7. Expert Consensus Opinion: MET molecular testing is not indicated as a routine stand-alone assay outside the context of
a clinical trial. It is appropriate to include MET as part of larger testing panels performed either initially or when routine
EGFR, ALK, BRAF, and ROS1 testing is negative.
Key Question 2: What methods should be used to perform molecular testing?

8. Recommendation: IHC is an equivalent alternative to FISH for ALK testing.
CAP/IASLC/AMP Qualifying Statement: ALK IHC is an acceptable standard alternative to FISH, and treatment decisions can be
made when IHC results are clearly positive, as manifested by strong granular cytoplasmic staining, with or without membrane accentuation,
or negative; however, weak staining can be challenging to interpret, and the speciﬁcity of weak staining relative to FISH should be determined
in each laboratory during validation.

9. Expert Consensus Opinion: Multiplexed genetic sequencing panels are preferred where available over multiple singlegene tests to identify other treatment options beyond EGFR, ALK, BRAF, and ROS1.
10. Expert Consensus Opinion: Laboratories should ensure that test results that are unexpected, discordant, equivocal, or
otherwise of low conﬁdence are conﬁrmed or resolved by using an alternative method or sample.
Key Question 3: Is molecular testing appropriate for lung cancers that do not have an adenocarcinoma component?

11. Expert Consensus Opinion: Physicians may use molecular biomarker testing in tumors with:
a. an adenocarcinoma component;
b. nonsquamous, non–small-cell histology;
c. any non–small-cell histology when clinical features indicate a higher probability of an oncogenic driver (eg, young age
[, 50 years]; light or absent tobacco exposure).
Key Question 4: What testing is indicated for patients with targetable mutations who have relapsed on targeted therapy?

12. Strong Recommendation: In patients with lung adenocarcinoma who harbor sensitizing EGFR mutations and have
progressed after treatment with an EGFR-targeted TKI, physicians must use EGFR T790M mutational testing when
selecting patients for third-generation EGFR-targeted therapy.
13. Recommendation: Laboratories testing for EGFR T790M mutation in patients with secondary clinical resistance to
EGFR-targeted kinase inhibitors should deploy assays capable of detecting EGFR T790M mutations in as little as 5% of
viable cells.
14. No Recommendation: There is currently insufﬁcient evidence to support a recommendation for or against routine
testing for ALK mutational status for patients with lung adenocarcinoma with sensitizing ALK mutations who have
progressed after treatment with an ALK-targeted TKI.
Key Question 5: What is the role of testing for circulating cell-free DNA (cfDNA) for patients with lung cancer?

15. No Recommendation: There is currently insufﬁcient evidence to support the use of cfDNA molecular methods for the
diagnosis of primary lung adenocarcinoma.
16. Recommendation: In some clinical settings in which tissue is limited and/or insufﬁcient for molecular testing, physicians
may use a cfDNA assay to identify EGFR mutations.
17. Expert Consensus Opinion: Physicians may use cfDNA methods to identify EGFR T790M mutations in patients with
lung adenocarcinoma who have progression or secondary clinical resistance to EGFR-targeted TKIs; testing of the tumor
sample is recommended if the plasma result is negative.
18. No Recommendation: There is currently insufﬁcient evidence to support the use of circulating tumor cell molecular
analysis for the diagnosis of primary lung adenocarcinoma, the identiﬁcation of EGFR or other mutations, or the
identiﬁcation of EGFR T790M mutations at the time of EGFR TKI resistance.
(continued on following page)
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THE BOTTOM LINE (CONTINUED)
Additional Resources: More information, including a Methodology Supplement with information about evidence quality and
strength of recommendations, slide sets, and clinical tools and resources, is available at www.asco.org/thoracic-cancer-guidelines and
www.asco.org/guidelineswiki. Patient information is available at www.cancer.net.
A link to the CAP/IASLC/AMP Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with
Targeted Tyrosine Kinase Inhibitors can be found at http://www.archivesofpathology.org/doi/pdf/10.5858/arpa.2017-0388-CP
Recommendations reprinted from Lindeman NI, Cagle, PT, Aisner, DL, et al. Updated Molecular Testing Guideline for the Selection
of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists,
the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. Arch Pathol Lab Med.
doi: 10.5858/arpa.2017-0388-CP, published online ahead of print November 2017, with permission from Archives of Pathology & Laboratory
Medicine. Copyright 2017 College of American Pathologists.
ASCO believes that cancer clinical trials are vital to inform medical decisions and improve cancer care, and that all patients should
have the opportunity to participate.

Association for the Study of Lung Cancer (IASLC)/Association for
Molecular Pathology (AMP) issued a joint guideline for molecular
testing for the selection of patients with lung cancer for epidermal
growth factor receptor (EGFR) and anaplastic lymphoma kinase
(ALK) TKIs.2 ASCO endorsed that guideline,3 which included
recommendations for selecting patients for testing, samples to be
tested, and testing methodology. Because the ﬁeld of molecular
pathology and options for targeted therapy have advanced since
the ﬁrst edition was published, CAP/IASLC/AMP recently
updated their guideline to incorporate new evidence related to
molecular testing for selecting patients with lung cancer for
treatment with targeted TKIs. The purpose of this update was to
provide recommendations for an expanded list of biomarkers
that should routinely be tested and to incorporate new evidence

for laboratory techniques, patient populations, and tumor types
that should be tested. As a result of the update, the 2013 recommendations were largely reafﬁrmed, with the exception of
a small number of statements that underwent minor modiﬁcations to incorporate new evidence. In addition, 18 new recommendations were developed by the CAP/IASLC/AMP Expert
Panel (Appendix Table A1, online only).
The purpose of this ASCO guideline is to critically appraise
and endorse the updated CAP/IASLC/AMP guideline on molecular
testing for selection of patients with lung cancer for treatment with
targeted TKIs. This endorsement reinforces the recommendations provided in the CAP/IASLC/AMP guideline and acknowledges the effort put forth by CAP/IASLC/AMP to produce an
evidence-based guideline informing practitioners who care for

Table 1. Recommendations for Endorsement That Have Been Reafﬁrmed or Updated From the 2013 Version
CAP/IASLC/AMP Recommendation

ASCO Endorsed Recommendation (with modiﬁcations in bold italics)

Expert Consensus Opinion: Pathologists may use either cell
blocks or other cytologic preparations as suitable specimens
for lung cancer biomarker molecular testing.
Expert Consensus Opinion: Laboratories should use, or have
available at an external reference laboratory, clinical lung
cancer biomarker molecular testing assays that are able to
detect molecular alterations in specimens with as little as
20% cancer cells.
Strong Recommendation: Laboratories should not use total
epidermal growth factor receptor (EGFR) expression by
immunohistochemistry testing to select patients for EGFRtargeted tyrosine kinase inhibitor (TKI) therapy.
Recommendation: Physicians should use molecular testing for
the appropriate genetic targets on either primary or
metastatic lung lesions to guide initial therapy selection.
Recommendation: Pathologists and laboratories should not use
EGFR copy number analysis (ie, ﬂuorescent in situ
hybridization or chemiluminescent in situ hybridization) to
select patients for EGFR-targeted TKI therapy.

Expert Consensus Opinion: Pathologists may use either cell blocks or
smear preparations as suitable specimens for lung cancer
biomarker molecular testing.
Expert Consensus Opinion: Laboratories should use, or have
available at an external reference laboratory, clinical lung cancer
biomarker molecular testing assays that are able to detect
molecular alterations in specimens with as little as 20% cancer
cells.
Strong Recommendation: Laboratories should not use EGFR
expression by immunohistochemistry testing to select patients for
EGFR-targeted TKI therapy.
Recommendation: Physicians should use molecular testing for the
appropriate genetic targets on either primary or metastatic lung
lesions to guide initial therapy selection.
Recommendation: Pathologists and laboratories should not use
EGFR copy number analysis (ie, ﬂuorescent in situ hybridization or
chemiluminescent in situ hybridization) to select patients for EGFRtargeted TKI therapy.

NOTE. Reprinted from Lindeman NI, Cagle, PT, Aisner, DL, et al. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With
Targeted Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association
for Molecular Pathology. Arch Pathol Lab Med. doi: 10.5858/arpa.2017-0388-CP, published online ahead of print November 2017, with permission from Archives of
Pathology & Laboratory Medicine. Copyright 2017 College of American Pathologists.

914

© 2018 by American Society of Clinical Oncology

Downloaded from ascopubs.org by Henry Ford Hospital on December 12, 2019 from 150.198.017.009
Copyright © 2019 American Society of Clinical Oncology. All rights reserved.

JOURNAL OF CLINICAL ONCOLOGY

Molecular Testing for Patients With Lung Cancer

Table 2. Comparison of CAP/IASLC/AMP Recommendations and ASCO Endorsed Recommendations
ASCO Endorsed Recommendation (with modiﬁcations or
qualifying statements in bold italics)

CAP/IASLC/AMP Recommendation
Key Question 1: Which genes should be tested for patients with
lung cancer?
Recommendation: ROS1 testing should be performed on all
patients with advanced lung adenocarcinoma, irrespective of
clinical characteristics.
Expert Consensus Opinion: ROS1 immunohistochemistry (IHC)
may be used as a screening test in patients with advanced
lung adenocarcinoma; however, positive ROS1 IHC results
should be conﬁrmed by a molecular or cytogenetic method.
Expert Consensus Opinion: BRAF molecular testing is currently
not indicated as a routine stand-alone assay outside the
context of a clinical trial. It is appropriate to include BRAF as
part of larger testing panels performed either initially or when
routine EGFR, ALK, and ROS1 testing is negative.
Expert Consensus Opinion: RET molecular testing is not
recommended as a routine stand-alone assay outside the
context of a clinical trial. It is appropriate to include RET as
part of larger testing panels performed either initially or when
routine EGFR, ALK, and ROS1 testing is negative.
Expert Consensus Opinion: ERBB2 (HER2) molecular testing is
not indicated as a routine stand-alone assay outside the
context of a clinical trial. It is appropriate to include ERBB2
(HER2) mutation analysis as part of a larger testing panel
performed either initially or when routine EGFR, ALK, and
ROS1 testing is negative.
Expert Consensus Opinion: KRAS molecular testing is not
indicated as a routine stand-alone assay as a sole
determinant of targeted therapy. It is appropriate to include
KRAS as part of larger testing panels performed either initially
or when routine EGFR, ALK, and ROS1 testing is negative.
Expert Consensus Opinion: MET molecular testing is not
indicated as a routine stand-alone assay outside the context
of a clinical trial. It is appropriate to include MET as part of
larger testing panels performed either initially or when routine
EGFR, ALK, and ROS1 testing is negative.
Key Question 2: What methods should be used to perform
molecular testing?
Recommendation: IHC is an equivalent alternative to
ﬂuorescent in situ hybridization (FISH) for ALK testing.

ROS1 testing should be performed on all patients with
advanced lung adenocarcinoma, irrespective of clinical
characteristics.
ROS1 IHC may be used as a screening test in patients with
advanced lung adenocarcinoma; however, positive ROS1
IHC results should be conﬁrmed by a molecular or
cytogenetic method.
BRAF testing should be performed on all patients with
advanced lung adenocarcinoma, irrespective of clinical
characteristics.

RET molecular testing is not recommended as a routine standalone assay outside the context of a clinical trial. It is
appropriate to include RET as part of larger testing panels
performed either initially or when routine EGFR, ALK, BRAF,
and ROS1 testing is negative.
ERBB2 (HER2) molecular testing is not indicated as a routine
stand-alone assay outside the context of a clinical trial. It is
appropriate to include ERBB2 (HER2) mutation analysis as
part of a larger testing panel performed either initially or when
routine EGFR, ALK, BRAF, and ROS1 testing is negative.
KRAS molecular testing is not indicated as a routine stand-alone
assay as a sole determinant of targeted therapy. It is
appropriate to include KRAS as part of larger testing panels
performed either initially or when routine EGFR, ALK, BRAF,
and ROS1 testing is negative.
MET molecular testing is not indicated as a routine stand-alone
assay outside the context of a clinical trial. It is appropriate to
include MET as part of larger testing panels performed either
initially or when routine EGFR, ALK, BRAF, and ROS1 testing
is negative.

IHC is an equivalent alternative to FISH for ALK testing.
CAP/IASLC/AMP Qualifying Statement: ALK IHC is an
acceptable standard alternative to FISH, and treatment
decisions can be made when IHC results are clearly positive,
as manifested by strong granular cytoplasmic staining with or
without membrane accentuation, or negative; however, weak
staining can be challenging to interpret, and the specificity of
weak staining relative to FISH should be determined in each
laboratory during validation.
Multiplexed genetic sequencing panels are preferred, where
available, over multiple single-gene tests to identify other
treatment options beyond EGFR, ALK, BRAF, and ROS1.

Expert Consensus Opinion: Multiplexed genetic sequencing
panels are preferred over multiple single-gene tests to
identify other treatment options beyond EGFR, ALK, and
ROS1.
Expert Consensus Opinion: Laboratories should ensure that
test results that are unexpected, discordant, equivocal, or
otherwise of low conﬁdence are conﬁrmed or resolved using
an alternative method or sample.
Key Question 3: Is molecular testing appropriate for lung
cancers that do not have an adenocarcinoma component?
Expert Consensus Opinion: Physicians may use molecular
biomarker testing in tumors with histologies other than
adenocarcinoma when clinical features indicate a higher
probability of an oncogenic driver.

Laboratories should ensure that test results that are
unexpected, discordant, equivocal, or otherwise of low
conﬁdence are conﬁrmed or resolved using an alternative
method or sample.

Physicians may use molecular biomarker testing in tumors
with:
a. an adenocarcinoma component;
b. nonsquamous non–small-cell histology;
c. any non–small-cell histology when clinical features indicate
a higher probability of an oncogenic driver (eg, young age
[, 50 years]; light or absent tobacco exposure).

Key Question 4: What testing is indicated for patients with
targetable mutations who have relapsed on targeted
therapy?
(continued on following page)
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Table 2. Comparison of CAP/IASLC/AMP Recommendations and ASCO Endorsed Recommendations (continued)
CAP/IASLC/AMP Recommendation
Strong Recommendation: In patients with lung
adenocarcinoma who harbor sensitizing EGFR mutations and
have progressed after treatment with an EGFR-targeted
tyrosine kinase inhibitor (TKI), physicians must use EGFR
T790M mutational testing when selecting patients for thirdgeneration EGFR-targeted therapy.
Recommendation: Laboratories testing for EGFR T790M
mutation in patients with secondary clinical resistance to
EGFR-targeted TKIs should deploy assays capable of
detecting EGFR T790M mutations in as little as 5% of viable
cells.
No Recommendation: There is currently insufﬁcient evidence
to support a recommendation for or against routine testing for
ALK mutational status for patients with lung adenocarcinoma
with sensitizing ALK mutations who have progressed after
treatment with an ALK-targeted TKI.
Key Question 5: What is the role of testing for circulating cellfree DNA (cfDNA) for patients with lung cancer?
No Recommendation: There is currently insufﬁcient evidence
to support the use of cfDNA molecular methods for the
diagnosis of primary lung adenocarcinoma.
Recommendation: In some clinical settings in which tissue is
limited and/or insufﬁcient for molecular testing, physicians
may use a plasma cfDNA assay to identify EGFR mutations.
Expert Consensus Opinion: Physicians may use plasma cfDNA
methods to identify EGFR T790M mutations in patients with
lung adenocarcinoma with progression or secondary clinical
resistance to EGFR-targeted TKIs; testing of the tumor
sample is recommended if the plasma result is negative.
No Recommendation: There is currently insufﬁcient evidence
to support the use of circulating tumor cell molecular analysis
for the diagnosis of primary lung adenocarcinoma, the
identiﬁcation of EGFR or other mutations, or the identiﬁcation
of EGFR T790M mutations at the time of EGFR TKI
resistance.

ASCO Endorsed Recommendation (with modiﬁcations or
qualifying statements in bold italics)
In patients with lung adenocarcinoma who harbor sensitizing
EGFR mutations and have progressed after treatment with an
EGFR-targeted TKI, physicians must use EGFR T790M
mutational testing when selecting patients for thirdgeneration EGFR-targeted therapy.
Laboratories testing for EGFR T790M mutation in patients with
secondary clinical resistance to EGFR-targeted TKIs should
deploy assays capable of detecting EGFR T790M mutations
in as little as 5% of viable cells.
There is currently insufﬁcient evidence to support
a recommendation for or against routine testing for ALK
mutational status for patients with lung adenocarcinoma with
sensitizing ALK mutations who have progressed after
treatment with an ALK-targeted TKI.

There is currently insufﬁcient evidence to support the use of
cfDNA molecular methods for the diagnosis of primary lung
adenocarcinoma.
In some clinical settings in which tissue is limited and/or
insufﬁcient for molecular testing, physicians may use
a plasma cfDNA assay to identify EGFR mutations.
Physicians may use plasma cfDNA methods to identify EGFR
T790M mutations in patients with lung adenocarcinoma with
progression or secondary clinical resistance to EGFRtargeted TKIs; testing of the tumor sample is recommended
if the plasma result is negative.
There is currently insufﬁcient evidence to support the use of
circulating tumor cell molecular analysis for the diagnosis of
primary lung adenocarcinoma, the identiﬁcation of EGFR or
other mutations, or the identiﬁcation of EGFR T790M
mutations at the time of EGFR TKI resistance.

NOTE. Reprinted from Lindeman NI, Cagle, PT, Aisner, DL, et al. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With
Targeted Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association
for Molecular Pathology. Arch Pathol Lab Med. doi: 10.5858/arpa.2017-0388-CP, published online ahead of print November 2017, with permission from Archives of
Pathology & Laboratory Medicine. Copyright 2017 College of American Pathologists.
Abbreviations: AMP, Association for Molecular Pathology; CAP, College of American Pathologists; IASLC, International Association for the Study of Lung
Cancer.

patients with lung cancer. The CAP/IASLC/AMP recommendations are listed in the Bottom Line Box, with qualifying
statements from the ASCO Endorsement Panel. The full CAP/IASLC/
AMP guideline is available at http://www.archivesofpathology.org/
doi/pdf/10.5858/arpa.2017-0388-CP.

OVERVIEW OF THE ASCO GUIDELINE ENDORSEMENT PROCESS

The American Society of Clinical Oncology (ASCO) has
policies and procedures for endorsing practice guidelines that
have been developed by other professional organizations. The
goal of guideline endorsement is to increase the number of
high-quality, ASCO-vetted guidelines available to the ASCO
membership. The ASCO endorsement process involves an
assessment by ASCO staff of candidate guidelines for methodologic quality using the “Rigour of Development” subscale
of the Appraisal of Guidelines for Research and Evaluation II
(AGREE II) instrument (see Methodology Supplement for
more detail.)
916

Disclaimer
The clinical practice guidelines and other guidance published
herein are provided by the American Society of Clinical Oncology,
Inc. (“ASCO”) to assist providers in clinical decision making. The
information therein should not be relied upon as being complete or
accurate, nor should it be considered as inclusive of all proper
treatments or methods of care or as a statement of the standard of
care. With the rapid development of scientiﬁc knowledge, new
evidence may emerge between the time information is developed
and when it is published or read. The information is not continually updated and may not reﬂect the most recent evidence. The
information addresses only the topics speciﬁcally identiﬁed therein
and is not applicable to other interventions, diseases, or stages of
diseases. This information does not mandate any particular course
of medical care. Further, the information is not intended to substitute for the independent professional judgment of the treating
provider, as the information does not account for individual variation among patients. Recommendations reﬂect high, moderate, or
low conﬁdence that the recommendation reﬂects the net effect of
a given course of action. The use of words like “must,” “must not,”
“should,” and “should not” indicate that a course of action is
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recommended or not recommended for either most or many patients, but there is latitude for the treating physician to select other
courses of action in individual cases. In all cases, the selected
course of action should be considered by the treating provider in
the context of treating the individual patient. Use of the information is voluntary. ASCO provides this information on an “as
is” basis, and makes no warranty, express or implied, regarding the
information. ASCO speciﬁcally disclaims any warranties of
merchantability or ﬁtness for a particular use or purpose. ASCO
assumes no responsibility for any injury or damage to persons or
property arising out of or related to any use of this information or
for any errors or omissions.

Guideline and Conflicts of Interest
The Expert Panel was assembled in accordance with ASCO’s
Conﬂict of Interest Policy Implementation for Clinical Practice
Guidelines (“Policy,” found at http://www.asco.org/rwc). All members
of the Expert Panel completed ASCO’s disclosure form, which requires
disclosure of ﬁnancial and other interests, including relationships with
commercial entities that are reasonably likely to experience direct
regulatory or commercial impact as a result of promulgation of the
guideline. Categories for disclosure include Employment; Leadership; Stock or Other Ownership; Honoraria, Consulting or Advisory
Role; Speaker’s Bureau; Research Funding; Patents, Royalties, Other
Intellectual Property; Expert Testimony; Travel, Accommodations,
Expenses; and Other Relationships. In accordance with the Policy,
the majority of the members of the Expert Panel did not disclose any
relationships constituting a conﬂict under the Policy.

GUIDELINE QUESTIONS

This clinical practice guideline addresses ﬁve overarching clinical
questions: (1) Which new genes should be tested for in patients with
lung cancer? (2) What methods should be used to perform molecular testing? (3) Is molecular testing appropriate for lung cancers
that do not have an adenocarcinoma component? (4) What testing
is indicated for patients with a targetable mutation who have relapsed on targeted therapy? (5) What is the role of testing for circulating cell-free DNA (cfDNA) for patients with lung cancer?

SUMMARY OF THE CAP/IASLC/AMP GUIDELINE
DEVELOPMENT METHODOLOGY

The Molecular Testing Guideline for the Selection of Lung Cancer
Patients for Treatment with Targeted Tyrosine Kinase Inhibitors
was updated jointly by CAP, IASLC, and AMP. A systematic
search of MEDLINE (Ovid Technologies, New York, NY) and
PubMed from January 1, 2012, to June 27, 2016, was conducted.
Additional searches were conducted in Scopus (Amsterdam, the
Netherlands) to identify publications not indexed in MEDLINE.
The clinicaltrials.gov Web site, guideline repository sites such as
the National Guidelines Clearinghouse (guidelines.gov) and the
Guidelines International Network (g-i-n.net), and other organizational Web sites were also searched. Details of the search strategies,
the study inclusion criteria, and outcomes of interest are available
jco.org

at http://www.archivesofpathology.org/doi/pdf/10.5858/arpa.20170388-CP. The searches identiﬁed 21 studies for inclusion in the
guideline’s update of the 2013 CAP/IASLC/AMP recommendations
and 118 articles that met the inclusion criteria for the questions that
were new to this update. The three participating organizations
convened an Expert Panel that included practicing pathologists and
oncologists with expertise in lung carcinoma, which met three
times by teleconference and two times in person to develop the
scope, draft recommendations, review and respond to solicited
feedback, and assess the quality of evidence. The guideline draft was
posted on the AMP Web site for an open comment period that took
place between June 28, 2016, and August 2, 2016. Feedback from
this process was incorporated into the draft guideline. Finally, each
of the three organizations instituted a separate review process to
approve the guideline.

METHODS AND RESULTS OF THE ASCO REVIEW

An initial methodology review of the Molecular Testing for the
Selection of Lung Cancer Patients for Treatment with Targeted
Tyrosine Kinase Inhibitors was completed using the Rigour of
Development subscale from the AGREE II instrument. Overall, the
guideline scored 96% (Methodology Supplement). Detailed results
of the scoring for this guideline are available upon request at
guidelines@asco.org. Three content experts provided a preliminary
ASCO review of the guideline. They found that the recommendations were well supported and suggested that the recommendations
could be endorsed with the appropriate minor modiﬁcations. Each
section, including the Introduction, Methods, Results, Recommendations, Conclusions, and Supplemental Material were clear
and well referenced from the systematic review. After these initial
methodology and content reviews, the ASCO Lung Biomarkers
Endorsement Panel, which consisted of individuals with expertise in
medical oncology, surgical oncology, pathology, pulmonology,
radiology, and guideline development methodology, was formed
and proceeded to meet via teleconference to review and discuss the
Molecular Testing for the Selection of Lung Cancer Patients for
Treatment with Targeted Tyrosine Kinase Inhibitors guideline.
CAP/IASLC/AMP guideline development methods call for
a review of the current guideline when practice-changing evidence
is published or, at most, 4 years after publication. Because the
ASCO Endorsement Panel was aware that the CAP/IASLC/
AMP Expert Panel would be continuously monitoring the
literature for signals that the guideline should be updated, the
ASCO Panel chose not to conduct an additional review of the
literature as part of this endorsement process. Therefore, the
evidence base for this guideline is current to the ﬁnal search
date of the CAP/IASLC/AMP search strategy. However, the
ASCO Endorsement Panel did consider the new US Food and
Drug Administration (FDA) approval of stand-alone BRAF
testing in 2017 during its endorsement process.
The Panel discussed each recommendation and agreed that
the recommendations were generally clear, thorough, and based on
the most relevant scientiﬁc evidence in this content area and that
they present options that will be acceptable to patients. Overall,
the ASCO Expert Panel agreed with the recommendations as stated
in the guideline, with minor qualiﬁcations, which are outlined
© 2018 by American Society of Clinical Oncology
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in the Bottom Line Box and described in the Endorsement Recommendation section. All funding for the administration of the
project was provided by ASCO.
This is the most recent information as of the publication date.
For updates and the most recent information and to submit new
evidence, please visit www.asco.org/thoracic-cancer-guidelines and
the ASCO Guidelines Wiki (www.asco.org/guidelineswiki).

ENDORSEMENT RECOMMENDATION

CAP/IASLC/AMP chose to update the joint guideline on molecular
testing to incorporate advances in the ﬁeld that have occurred since
publication of the previous version.2 ASCO endorses this update
with minor modiﬁcations by the ASCO Expert Panel, as presented
in the Bottom Line Box and discussed here. The ASCO Panel also
included text from the CAP/IASLC/AMP narrative to provide
context for two of the endorsed recommendations. A qualifying
statement from the CAP/IASLC/AMP narrative was added to
recommendation 8 on ALK immunohistochemistry (IHC) to
clarify the signiﬁcance of strong, negative, or weak granular cytoplasmic staining. The CAP/IASLC/AMP recommendation on
ALK IHC was based on published evidence that tests based on the
5A4 and D5F3 monoclonal antibodies showed sensitivities and
speciﬁcities ranging from 95% to 100%. For recommendation 11,
the Panel also added text from the original CAP/IASLC/AMP
document to provide clariﬁcation of clinical and pathologic factors that warrant molecular biomarker testing for oncogenic
drivers, particularly in tumors with histologic components other
than adenocarcinoma. In addition, in updated/modiﬁed recommendation 1, the ASCO Panel speciﬁcally indicated smear preparations as cytologic preparations other than cell blocks that,
although not preferred, would be suitable as specimens for lung
cancer biomarker testing. With regard to recommendation 17, in
their discussions, the ASCO Panel also noted that for patients with
EGFR-mutated non–small-cell lung cancer in whom cfDNA testing
does not reveal a T790M mutation, direct tumor sampling may be
helpful in identifying not only a T790M mutation but also other
mechanisms of secondary resistance such as neuroendocrine
differentiation or alternative genetic mutations.
The CAP/IASLC/AMP recommendation related to BRAF
testing in patients with advanced adenocarcinoma was not endorsed
by the ASCO Panel. When CAP/IASLC/AMP originally drafted
updated recommendations, BRAF testing had not yet been approved
by the FDA. However, the FDA has since granted approval for standalone BRAF testing. Therefore, the ASCO panel chose to incorporate
this into the recommendations and to recommend BRAF testing for
all patients with advanced lung adenocarcinoma. FDA approval was
based on a 2016 phase II single-arm trial1 showing a disease control
rate (DCR) of 58% with second-line therapy with dabrafenib and
a DCR of 75% with second-line therapy with dabrafenib plus trametinib in patients with stage IV non–small-cell lung cancer who
had BRAF V600E mutations.4 The CAP/IASLC/AMP Expert Panel
indicated awareness of the FDA approval in their guideline narrative
and stated that they will most likely recommend stand-alone BRAF
testing in the next iteration of their guideline. Following this
modiﬁcation to the CAP/IASLC/AMP recommendations, the ASCO
Expert Panel also chose to add BRAF testing to the routine tests listed
918

in recommendations 4 through 7 for other molecular markers as well
as to recommendation 9 for multiplexed genetic sequencing panels.
The Endorsement Panel agreed with the conclusions of the
CAP/IASLC/AMP Expert Panel that there was adequate evidence
to support the recommendation for ROS1 testing in patients with
advanced-stage adenocarcinoma.1 ROS1 testing has been approved by the FDA based on a 50-person phase I clinical trial that
demonstrated a 72% response rate to targeted therapy with
crizotinib in patients with ROS1-rearranged non–small-cell lung
cancer.5 An additional 32-patient retrospective study demonstrated
an 80% rate of response for patients with ROS1-rearranged non–
small-cell lung cancer who were treated with crizotinib.6
The ASCO Expert Panel also noted that, as is true for all
guidelines, the interpretation and implementation of some of the
statements may be inﬂuenced by the geographic location and the
practice setting (academic v community). This may particularly be
true for the statements that lack robust evidence and are either
primarily consensus opinions or for statements that have no recommendation for or against a particular issue. There was discussion
within the Expert Panel and the ASCO Clinical Practice Guidelines
Committee regarding the cost of multiplexed genomic sequencing
panels, and it was concluded that multiplexed panels are likely to be
more efﬁcient in terms of cost and tumor tissue requirements. For
patients in whom initial testing (multiplex or sequential) for EGFR
and BRAF mutations as well as ALK and ROS1 rearrangements or
fusions is negative, further genomic testing may be considered
depending upon the hospital/institutional and geographic setting,
and a decision to this effect may be made after discussion with the
patient. However, a detailed discussion of this aspect is beyond the
scope of the current guideline and endorsement.
ASCO guidelines are developed for implementation across health
settings. Barriers to implementation include the need to increase
awareness of the guideline recommendations among front-line
practitioners, survivors of cancer, and caregivers and also to provide adequate services in the face of limited resources. The guideline
Bottom Line Box was designed to facilitate implementation of recommendations. This guideline will be distributed widely through the
ASCO Practice Guideline Implementation Network. ASCO guidelines
are posted on the ASCO Web site and most often published in Journal
of Clinical Oncology and Journal of Oncology Practice.
ASCO and the Expert Panel are aware that CAP/IASLC/AMP is
monitoring the literature for the latest substantive publications in the
ﬁeld of molecular testing and that they plan to update their guideline
when new high-quality practice-changing evidence becomes available.
One area of future research that was identiﬁed during the guideline
review process was the consideration of rebiopsy after progression on
an ALK inhibitor to identify secondary ALK mutations that might
guide the use of next-generation ALK inhibitors. ASCO will continue
to follow CAP/IASLC/AMP’s guideline development updates on this
topic and will incorporate future versions into our endorsement
process as they become available.

ADDITIONAL RESOURCES

More information, including a Methodology Supplement, slide
sets, and clinical tools and resources, is available at www.asco.org/
thoracic-cancer-guidelines and www.asco.org/guidelineswiki.
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Patient information is available at www.cancer.net. Visit www.asco.
org/guidelineswiki to provide comments on the guideline or to
submit new evidence.

Disclosures provided by the authors are available with this article at
jco.org.
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